|
Therapy-related Myelodysplastic Syndromes Deserve Specific Diagnostic Sub-Classification and Risk-Stratification-An Approach to Classification of Patients With t-MDS
|
Jun 2020
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Therapy-related myelodysplastic syndromes in the genomics era
|
Jun 2023
|
Bulletin du Cancer
|
myelodysplastic syndromes (MDS)
|
|
Therapy-related myelodysplastic syndromes, or are they?
|
Nov 2016
|
Blood Rev
|
myelodysplastic syndromes (MDS)
|
|
Therapy-related myelodysplastic syndromes-specific risk stratification: Are we putting the cart before the horse?
|
Jul 2017
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
There's Risk, and Then There's RISK: The Latest Clinical Prognostic Risk Stratification Models in Myelodysplastic Syndromes.
|
Aug 2013
|
Curr Hematol Malig Rep
|
myelodysplastic syndromes (MDS)
|
|
Thrombopoiesis-stimulating agents and myelodysplastic syndromes
|
Feb 2015
|
Br J Haematol
|
myelodysplastic syndromes (MDS)
|
|
Thrombosis in paroxysmal nocturnal hemoglobinuria.
|
Apr 2013
|
Blood
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Thrombotic complications without evidence of hemolysis in paroxysmal nocturnal hemoglobinuria: is eculizumab indicated?
|
Jul 2012
|
Ann Hematol
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Time without transfusion reliance: a novel patient-centric metric for new therapies in myelodysplastic syndromes
|
Apr 2023
|
Haematologica
|
myelodysplastic syndromes (MDS)
|
|
Timing of allogeneic stem cell transplantation for myelodysplastic syndromes and aplastic anemia
|
Dec 2014
|
Hematology Am Soc Hematol Educ Program
|
aplastic anemia
|
